GLP-1 Picks and Shovels
Geet Khosla@khosla
+2.4%
since Oct 6
The idea
I believe GLP-1 demand keeps growing for a decade, and the real bottleneck isn't the drug itself but the capacity to make and deliver it. So this basket spreads across the whole supply chain: peptide manufacturing and bioprocessing, glass and fill-finish, pens and autoinjectors, testing gear, and distribution, anchored by steady large-caps with smaller pure-plays for sharper upside. No single name dominates, pens stay in deliberately even with oral GLP-1 risk, and a small cash buffer rounds it out.
What it owns
- Someone has to manufacture billions of doses of peptide, and these companies sell the equipment and materials that drugmakers need to build production capacity. · Thermo Fisher ScientificIt manufactures peptides at scale for drugmakers that outsource production, earning revenue regardless of which GLP-1 wins as long as capacity buildout continues., DanaherIt sells bioprocessing equipment and consumables that new peptide manufacturing plants require, capturing orders from a decade of GLP-1 capacity buildout., AvantorIt supplies the chemicals and lab materials that peptide production uses batch after batch, a repeat-purchase business tied to manufacturing volume growth., RepligenIt makes filtration and purification consumables used in every peptide batch run, earning on volume regardless of which drug wins.27%
- Every injectable dose ships in specialized glass with specialized rubber stoppers, creating a tight bottleneck in the supply chain that few suppliers can fill. · West Pharmaceutical ServicesIt makes the stoppers and plungers inside every injectable dose, a scarce-capacity supplier with few qualified competitors., Stevanato GroupIt makes the glass cartridges and pen systems that injectable GLP-1s ship in, a direct exposure to the fill-and-deliver layer., CorningIt supplies pharmaceutical glass, and rising injectable volume means more vials and cartridges to fill over time., AptarGroupIt makes elastomer components and delivery systems for injectables, a toll on each dose that gets filled and shipped.26%
- Injectable GLP-1s require pens, needles, and automated assembly lines, a delivery layer that remains important even as oral versions enter the market. · Becton DickinsonIt supplies syringes, pen needles, and autoinjector capacity that GLP-1 makers need in large quantity, the steadiest player in the injection layer., ATS CorporationIt builds the automated assembly lines that assemble pens and autoinjectors, capturing orders when drugmakers expand injector capacity., EmbectaIt makes pen needles, the small disposable piece every injection uses, a pure play on maintaining injectable volumes.16%
- Peptide drugs require constant analytical testing throughout development and production, so instrument makers earn on every batch that gets approved and released. · Agilent TechnologiesIt sells instruments that analyze peptides during development and production, required by every new GLP-1 manufacturing plant., Mettler-ToledoIt supplies weighing and process instruments that go into every new pharmaceutical production line as part of the capacity buildout., WatersIt makes chromatography and testing systems that release every peptide batch, earning more as production volume increases., BrukerIt makes instruments that characterize peptide molecules through development and scale-up, earning from the R&D and quality side of GLP-1 manufacturing.16%
- Distributors physically move GLP-1 volume to pharmacies and earn a cut of one of the fastest-growing drug categories. · CencoraIt distributes GLP-1 drugs to pharmacies and earns on the volume that moves, growing as prescription demand climbs., McKessonIt moves GLP-1 boxes from manufacturers to pharmacies and earns on volume, so compounding prescription growth flows directly through its distribution network.8%
- Cash7%